X

Trial Profile

The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN): A Partnership With the CH.I.L.D. Foundation: Multi-center Inception Cohort Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Focus Therapeutic Use
Acronyms CIDsCANN

Most Recent Events

06 May 2021 New trial record
28 Apr 2021 Results (n=25) assessing examine the efficacy of ustekinumab in Ulcerative-colitis patients, published in the Alimentary Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com